2022 World Conference on Lung Cancer (ePosters)-EP08.02-130. Tegavivint Exhibits Antitumor Activity and Modulates Macrophage Phenotype in the Non-small Cell Lung Cancer Tumor Microenvironment

EP08.02-130. Tegavivint Exhibits Antitumor Activity and Modulates Macrophage Phenotype in the Non-small Cell Lung Cancer Tumor Microenvironment

Back to course

Pdf Summary

In summary, the study examined the efficacy of a small molecule inhibitor called Tegavivint on non-small cell lung cancer (NSCLC), specifically the lung adenocarcinoma (LUAD) subtype. Tegavivint targeted the Wnt/β-catenin pathway, which is associated with tumor growth and poor prognosis. The study found that Tegavivint inhibited the expression of β-catenin and its downstream targets, leading to reduced cancer cell growth and viability. It also showed that high expression of β-catenin was associated with worse prognosis in LUAD-NSCLC patients.<br /><br />Additionally, the study investigated the effect of Tegavivint on the tumor microenvironment (TME) by modulating macrophage activity. Tegavivint was found to reduce the expression of Arginase-1 (Arg1) in macrophages, which are associated with an immunosuppressive phenotype. In in vivo experiments, Tegavivint therapy restricted tumor growth and weight and potentially down-regulated immunosuppressive macrophages in tumor specimens.<br /><br />Overall, the study suggests that targeting the Wnt/β-catenin pathway with Tegavivint could be a promising therapeutic approach for improving outcomes in LUAD-NSCLC patients, by inhibiting cancer cell growth and modulating the tumor microenvironment to reduce immunosuppressive macrophages.

Asset Subtitle

Raghav Chandra

Meta Tag

Speaker Raghav Chandra

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

Tegavivint

non-small cell lung cancer

Wnt/β-catenin pathway

tumor growth

cancer cell growth

prognosis

tumor microenvironment

macrophage activity

immunosuppressive phenotype

therapeutic approach